The Group has strong R&D capabilities, supported by a high-caliber multidisciplinary R&D team and an experienced clinical development team. More than 95% of team members hold master's degrees or above, with expertise spanning 32 disciplines, including microbiology, microbial ecology, molecular biology, clinical medicine, traditional Chinese medicine, pharmacy, nutrition, bioinformatics, mathematics, and management. Together with the Xiamen Science and Technology Bureau and the Xiang'an District Government, the Group established the Xiamen Joint Institute of Respiratory Health. Together with the same local authorities, it established the Xiamen Institute of Nine-Constitution Medicine and Preventive Treatment Big Data. The Group operates nearly 10,000 square meters of microbiota R&D laboratories, has 13 drug-development pipelines in progress, and has obtained 280 intellectual property rights.

The Group operates six core technology platforms: the Precision Microbiota Transplantation Treatment Platform, Industrial Microbiota Extraction Platform, Microbiota Medical Devices Technology Platform, Clinical Microbiology Testing Technology Platform, Microecological Medical Big Data Cloud Platform, and Microbial Drug Screening and Development Platform. Built on precision microbiota transplantation, it provides five major solutions and operates a microbiota-bank-centered business system. Its seven microecology sectors—TreatGut Biology, TreatGut Medical, TreatGut Health, TreatGut Intelligent Pharmaceuticals, TreatGut Future Microecology Hospital, TreatGut Digital Intelligence, and TreatGut Consumption—form a complete closed-loop microecological healthcare system. The Group currently offers nine microbiota transplantation products and services for different indications, has obtained microbiota transplantation billing codes in 23 provinces, serves more than 300 medical institutions, and has completed over 330,000 microbiota transplantations and gut microbiota tests.

Looking ahead, TreatGut Pharmaceutical Group will provide hospitals with smarter, more convenient, and more precise microbiota transplantation technologies; identify candidate strains for microecological drugs; provide data support and technical services for personalized microecological preparations; and develop leading specialty microecology hospitals. It will also build a modern data integration center that enables interconnected data and provides the digital foundation for applications across microecological healthcare.